


PHARMACEUTICAL 2022



CHINOOK THERAPEUTICS INC. Rank 123 of 475





PHARMACEUTICAL 2022



CHINOOK THERAPEUTICS INC. Rank 123 of 475

The relative strengths and weaknesses of CHINOOK THERAPEUTICS INC. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of CHINOOK THERAPEUTICS INC. compared to the market average is the variable Other Assets, increasing the Economic Capital Ratio by 69% points. The greatest weakness of CHINOOK THERAPEUTICS INC. is the variable Other Expenses, reducing the Economic Capital Ratio by 12% points.

The company's Economic Capital Ratio, given in the ranking table, is 24%, being 300% points above the market average of -276%.

Input Variable	Value in 1000 USD
Assets, Current	300,639
Cost of Goods Sold	0
Intangible Assets	26,126
Liabilities, Current	40,085
Liabilities, Non-Current	39,589
Other Assets	218,103
Other Compr. Net Income	-66
Other Expenses	31,097
Other Liabilities	30,486
Other Net Income	5,421
Property and Equipment	18,935
Research and Development	96,987
Revenues	51,625
Selling, General and Administrative Expense	31,899

Output Variable	Value in 1000 USD
Assets	563,803
Liabilities	110,160
Expenses	159,983
Stockholders Equity	453,643
Net Income	-102,937
Comprehensive Net Income	-102,970
Economic Capital Ratio	24%